BACKGROUND
Familial combined hypolipidemia, a Mendelian condition characterized
by substantial reductions in all 3 major lipid fractions, is caused by
mutations that inactivate the gene angiopoietin-like 3
(ANGPTL3). Whether ANGPTL3 deficiency reduces risk of
coronary artery disease (CAD) is unknown.
OBJECTIVES
The study goal was to leverage 3 distinct lines of evidence –
a family that included individuals with complete (compound heterozygote)
ANGPTL3 deficiency, a population based-study of humans with partial
(heterozygote) ANGPTL3 deficiency, and biomarker levels in myocardial
infarction (MI) patients – to test if ANGPTL3 deficiency is
associated with lower risk for CAD.
METHODS
We assessed coronary atherosclerotic burden in 3 individuals with
complete ANGPTL3 deficiency and 3 wild-type first-degree relatives using
computed tomography angiography. In the population, ANGPTL3
loss-of-function (LOF) mutations were ascertained in up to 21,980
individuals with CAD and 158,200 controls. LOF mutations were defined as
nonsense, frameshift, and splice-site variants, along with missense variants
resulting in <25% of wild-type ANGPTL3 activity in a mouse model.
In a biomarker study, circulating ANGPTL3 concentration was measured in
1,493 individuals presenting with MI and 3,232 controls.
RESULTS
The 3 individuals with complete ANGPTL3 deficiency showed no evidence
of coronary atherosclerotic plaque. ANGPTL3 gene sequencing
demonstrated that approximately 1 in 309 individuals was a heterozygous
carrier for an LOF mutation. Compared to those without mutation,
heterozygous carriers of ANGPTL3 LOF mutations demonstrated
a 17% reduction in circulating triglycerides and a 12%
reduction in low-density lipoprotein cholesterol. Carrier status was
associated with a 34% reduction in odds of CAD (odds ratio: 0.66;
95% confidence interval: 0.44 to 0.98; p = 0.04).
Individuals in the lowest tertile of circulating ANGPTL3 concentrations,
compared with the highest, had reduced odds of MI (adjusted odds ratio:
0.65; 95% confidence interval: 0.55 to 0.77; p < 0.001).
CONCLUSIONS
ANGPTL3 deficiency is associated with protection from CAD.